Assessment of intratumor non-antibody directed iron oxide nanoparticle hyperthermia cancer therapy and antibody directed IONP uptake in murine and human cells

P. J. Hoopes, J. A. Tate, J. A. Ogden, R. R. Strawbridge, S. N. Fiering, A. A. Petryk, S. M. Cassim, A. J. Giustini, E. Demidenko, R. Ivkov, S. Barry, P. Chinn, A. Foreman

Research output: Contribution to journalConference article

Abstract

Hyperthermia, as an independent modality or in combination with standard cancer treatments such as chemotherapy and radiation, has been established in vitro and in vivo as an effective cancer treatment. However, despite efforts over the past 25 years, such therapies have never been optimized or widelyaccepted clinically. Although methods continue to improve, conventionally-delivered heat (RF, ultrasound, microwave etc) can not be delivered in a tumor selective manner. The development of antibody-targeted, or even nontargeted, biocompatible iron oxide nanoparticles (IONP) now allows delivery of cytotoxic heat to individual cancer cells. Using a murine mouse mammary adenocarcinoma (MTGB) and human colon carcinoma (HT29) cells, we studied the biology and treatment of IONP hyperthermia tumor treatment. Methods: Cancer cells (1 x 10 6) with or without iron oxide nanoparticles (IONP) were studied in culture or in vivo via implanted subcutaneously in female C3H mice, Tumors were grown to a treatment size of 150 mm3 and tumors volumes were measured using standard 3-D caliper measurement techniques. Mouse tumors were heated via delivery of an alternating magnetic field, which activated the nanoparticles, using a cooled 36 mm diameter square copper tube induction coil which provided optimal heating in 1.5 cm wide region of the coil. The IONPs were dextran coated and had a hydrodynamic radius of approximately 100 nm. For the in vivo studies, intra-tumor, peritumor and rectal (core body) temperatures were continually measured throughout the treatment period. Results: Although some eddy current heating was generated in non-target tissues at the higher field strengths, our preliminary IONP hyperthermia studies show that whole mouse AMF exposure @160 KHz and 400 or 550 Oe, for a 20 minutes (heat-up and protocol heating), provides a safe and efficacious tumor treatment. Initial electron and light microscopic studies (in vitro and in vivo) showed the 100 nm used in our studies are rapidly taken up and retained by the tumor cells. Additional in vitro studies suggest antibodies can significantly enhance the cellular uptake of IONPs.

Original languageEnglish (US)
Article number71810P
JournalProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume7181
DOIs
StatePublished - Jun 1 2009
EventEnergy-based Treatment of Tissue and Assessment V - San Jose, CA, United States
Duration: Jan 25 2009Jan 26 2009

Keywords

  • Alternating magnetic field
  • Antibody
  • Efficacy
  • Hyperthermia
  • Iron oxide
  • Mouse
  • MTG-B
  • Nanoparticle

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Assessment of intratumor non-antibody directed iron oxide nanoparticle hyperthermia cancer therapy and antibody directed IONP uptake in murine and human cells'. Together they form a unique fingerprint.

  • Cite this

    Hoopes, P. J., Tate, J. A., Ogden, J. A., Strawbridge, R. R., Fiering, S. N., Petryk, A. A., Cassim, S. M., Giustini, A. J., Demidenko, E., Ivkov, R., Barry, S., Chinn, P., & Foreman, A. (2009). Assessment of intratumor non-antibody directed iron oxide nanoparticle hyperthermia cancer therapy and antibody directed IONP uptake in murine and human cells. Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 7181, [71810P]. https://doi.org/10.1117/12.812056